NEWS & UPDATES

INTRODUCING ACCEL DIAGNOSTICS

Oct 15, 2012

AccelDx introduces (follow link) pScreen-BNP for the diagnosis of heart failure at the In3 Medical Summit 360.

Sept 1, 2012 
AccelDx receives
$524,000 NIH sponsored Phase I SBIR

June 19, 2012
AccelDx's secures OFEF funding

May 23, 2012
Follow AccelDx's Investor Pitch
http://vimeo.com/alphalab/acceldxdd

Feb 3, 2012 
AccelDx receives Innovation Works funding

Dec 13, 2011
AccelDx signs the technology exclusive licensing agreement from Carnegie Mellon University

Oct 25, 2011
AccelDx receives funding through the Enterprise Creation Award from Carnegie Mellon to develop the Company beta prototype


Accel Diagnostics is a medical technology company developing pScreenTM, a disposable protein test for the diagnosis, monitoring and management of a wide variety of medical conditions, including heart failure, cancer, osteoperosis, critical pregnancy, and infectious diseases. 

AccelDx's solution disrupts the current diagnostic market and creates new market opportunities in the Home and Point-of-Care settings. 

pScreenTM (check our demo-video) is the first self-contained disposable blood test to measure the level of proteins (disease biomarkers) from a single droplet of finger pricked blood, thereby enabling patients and doctors to perform diagnostic tests and access results within 30 minutes anytime anywhere. 

By providing timely, affordable, and accurate medical test results, Accel enables physicians to manage their patients and reach disease resolution in a timely and cost-effective manner, reducing cost and preventing hospitalizations. It also enables patients to monitor and effectively manage the progression of their chronic diseases in the comfort of their home. AccelDx's platform technology leverages a patent-protected magnetic microfluidic system developed at Carnegie Mellon University. 

In the news: 


Accel Diagnostics, LLC
1401 Forbes Avenue, Suite 401-3
Pittsburgh, PA 15213
Tel. + 1 412-355-0338
info@acceldx.com